SAN FRANCISCO, Oct. 27, 2016 /PRNewswire/ -- Fluxion Biosciences, Inc. the launch of the Spotlight 59 Oncology Panel.
Liquid biopsies are emerging as a powerful tool in cancer research, where the ability to detect and track cancer using non-invasive methods offers tremendous diagnostic potential. However, cancer DNA in blood samples is present at very low concentrations, to levels of 0.1% or below. Even with CTCs recovered from IsoFlux, which enrich cancer cell content to 5-25%, heterogeneity among the cancer cells can still produce samples with mutation levels below 1%. Fluxion overcomes this limitation with ERASE-Seq, its statistically driven bioinformatics solution. ERASE-Seq delivers unrivalled performance, with sensitivity to 0.1% allele frequency with no false positives detected across the Spotlight 59 panel.
The Spotlight 59 Oncology Panel offers comprehensive and hotspot coverage of 59 clinically-relevant oncology-related genes, using a 277-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms, without the need for complicated molecular barcodes. The panel, based on Swift Biosciences Accel-Amplicon™ chemistry, is a complete kit that includes all elements necessary for generating ready-to-sequence libraries, including primer pairs and indexed sequencing adapters.
According to Fluxion's CEO, Jeff Jensen, the Spotlight 59 Oncology Panel with ERASE-Seq represents a major advance in cancer clinical research. "A main limitation to broad adoption of liquid biopsies is achieving detection sensitivity without introducing false positives. Spotlight 59 with ERASE-Seq overcomes this limitation with a simplified, cost-effective workflow that every sequencing lab can adopt."
The Spotlight 59 panel (part number 910-0113) is available immediately and can be used with multiple sample types, including CTC samples from existing IsoFlux systems and kits. For more information about the Spotlight 59 Oncology Panel, visit fluxionbio.com/isoflux.
About Fluxion Biosciences
Fluxion's IsoFlux CTC Liquid Biopsy System is used in clinical research for early cancer detection and patient monitoring. The IsoFlux System utilizes a novel microfluidic capture technology to isolate and purify circulating tumor cells (CTCs) from a blood sample, enabling cost-effective early detection and ongoing monitoring of actionable mutations non-invasively via NGS. For more information about Fluxion Biosciences, visit fluxionbio.com.
Contact: Jeff Jensen 650 241 4777 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fluxion-biosciences-launches-spotlight-59-ngs-oncology-panel-for-liquid-biopsies-300352526.html
SOURCE Fluxion Biosciences
Subscribe to our Free Newsletters!
Adult immunization is needed for adults whose mandatory childhood vaccines were either missed out ...
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast ...View All